• OUTLOOK ARENA
  • VIEWS ON NEWS
  • OCTOBER 23, 2000

Cadila: poor man's Cipla

Cadila Healthcare has also made its mark in the domestic pharmaceutical market thanks to the reverse engineering. The company was formed after the spilt in the partnership between the Patel and Modi groups. (The latter own Cadila Pharmaceuticals).

(Rs m) 2QFQ00 2QFY01 Change
Sales 1,286 1,450 12.8%
Other Income 3 4 33.9%
Expenditure 1,086 1,197 10.3%
Operating Profit (EBDIT) 200 253  
Operating Profit Margin (%) 15.6% 17.5%  
Interest 33 (5) -113.8%
Depreciation 11 41 274.5%
Profit before Tax 159 221 38.6%
Other Adjustments      
Tax 15 30  
Profit after Tax/(Loss) 144 191 32.3%
Net profit margin (%) 11.2% 13.1%  
Earnings per share* 9.68 12.80  
(annualised)      

At the time of the public issue, the company was positioned in the league of Cipla. However, the stock price performance has been pathetic, to say the least. The stock quotes at Rs 114 and shareholders have actually lost more than 50% of their capital if they had invested at the time of the IPO.

The company second quarter's performance has been satisfactory vis–a–vis the growth of the overall industry. Cadila's net sales are up by 12.8% and its net profit has grown by 32.3%. The growth in post tax profit has been lead mainly by the repayment of debt which has reduced the interest cost. (To be fair to the company it has managed to improve its operating margins also, but the reduction in interest has been a key driver of earnings growth.) This is because the company still has not deployed a part of its IPO proceeds. (Of the Rs 3.72 bn that Cadila received during the time of the IPO, the company has so far utilised Rs 2.72 bn.)

The company derives 21% from anti–infectives, 20% from gastrointestinals, 8% from cardiovascular, 10% from vaccines and 8% from anti–inflammatory. It's main brands include Ciprobid (a ciprofloxacin based anti–infective), Ocid (omeprazole based gastrointestinal), Oxalgin (diclofenac sodium based pain management) and Oriprim (trimethoprim based anti–infective).

The stock quotes at a multiple of 9 times FY01 annualised earnings. What seems to have hit the valaution of the stock is the negative perception of the management and long drawn courtroom drama pitting the two former partners of the group. (There are as many as three court cases between the two companies at various stages of progress in the courts including the Supreme Court.)

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407